Source: Kane Biotech Inc.
  • Kane Biotech (KNE) has obtained ISO 13485:2016 certification for its quality management system
  • This is specific to its ongoing efforts to design and develop novel medical devices for the wound care market
  • ISO certification demonstrates Kane Biotech’s compliance, and customers can be assured that the medical devices designed and developed are fit for their intended purpose
  • Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms
  • Kane Biotech Inc. (KNE) was up 5.56 per cent, trading at C$0.095 per share at 11:50 am ET

Kane Biotech (KNE) has obtained ISO 13485:2016 certification for its quality management system.

This is in support of its ongoing efforts to design and develop novel medical devices for the wound care market.

Lori Christofalos, Vice President of quality & compliance at Kane Biotech commented on the news.

“Quality and continuous improvement are core values of Kane and of paramount importance to us. Our quality management policies, procedures, and practices have been established to demonstrate our commitment to this high standard and to support future global medical device registrations and approvals. It represents another big step as we continue to drive towards commercialization with our wound care portfolio.”

ISO certification demonstrates Kane Biotech’s compliance, and customers can be assured that the medical devices designed and developed are fit for their intended purpose.

ISO is an independent, non-governmental international organization with a membership of 167 national standards bodies. Through its members, it brings together experts to share knowledge and develop voluntary, consensus-based, market relevant International Standards that support innovation and provide solutions to global challenges.

The process of achieving ISO certification included establishing a quality management system and conducting an independent audit to verify conformance of records to the standards.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. 

Kane Biotech Inc. (KNE) was up 5.56 per cent, trading at C$0.095 per share at 11:50 am ET.

More From The Market Online

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.

Revolutionizing medical imaging with nanocarbon-based contrast drugs

The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals (TSXV:VM) is transforming carbon capture and reuse technology.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.

Theralase enhances cancer drug efficacy

Theralase Technologies (TSXV:TLT) announces its Ruvidar compound creates a new compound able to significantly kill more cancer cells.